Atrium Therapeutics, Inc.
Financials
Valuation Metrics
Atrium Therapeutics, Inc.'s Market Cap is $250M. Ranked #2995 of 3,116 in US market (top 96%), #1363 of 1,458 on NASDAQ (top 93%), #249 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $250M | US#2,995/3,116 Sec#249/266 |
| Total Assets | $281M | US#2,935/3,116 Sec#218/266 |
| Net Assets | $215M | US#2,669/3,116 Sec#191/266 |
| Employees | 511 | US#2,276/3,116 Sec#82/266 |
| Value | ||
| P/B | 1.16x | US#505/3,116 Sec#15/266 |
| P/S | 13.41x | US#2,765/3,116 Sec#121/266 |
| Financial Health | ||
| Debt Ratio | 30.73% | US#348/3,116 Sec#109/266 |
| Total Debt | $2M | US#2,977/3,116 Sec#238/266 |
| Cash | $73M | US#2,411/3,116 Sec#200/266 |
| Current Ratio | 8.73x | US#301/3,116 Sec#91/266 |
| Performance | ||
| 1M Return | 26.52% | US#136/3,116 Sec#28/266 |
| From 52W High | -12.94% | US#1,195/3,116 Sec#90/266 |
| 1Y MDD | -32.41% | US#1,599/3,116 Sec#104/266 |
| Trading | ||
| Volume | 164,711 shares | US#2,668/3,116 Sec#249/266 |
| Trading Value | $2M | US#2,850/3,116 Sec#242/266 |
| Per Share | ||
| BPS | $12.54 | US#1,676/3,116 Sec#57/266 |
Company Info
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.